Delayed-Release Methylphenidate Composition for All-Day ADHD Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for ADHD, such as stimulant medications, face challenges in maintaining effective drug concentration throughout the day, particularly during critical cognitive periods, due to traditional formulations requiring multiple daily administrations, leading to compliance issues and inconsistent therapeutic effects.
Innovation Solution
Development of novel oral pharmaceutical compositions with a core containing a CNS stimulant, coated with a sustained release layer and a delayed release layer, allowing for a single evening dose that provides a controlled release of the drug over 4 to 12 hours, ensuring therapeutic levels upon waking and throughout the day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immediate release formulations are used, then the drug can be administered twice daily, but compliance problems occur and therapeutic consistency is poor
Solution Approach 1:
The patent segments the drug delivery into two distinct functional layers: an immediate release layer that provides rapid initial drug delivery, and a sustained release layer that maintains therapeutic levels throughout the day. This segmentation allows the single daily dose to achieve both rapid onset and prolonged effect, resolving the contradiction between therapeutic consistency and compliance.
Solution Approach 2:
The patent changes the release rate parameter of the drug by using different coating materials with distinct release characteristics. The immediate release coating allows rapid drug release initially, while the sustained release coating maintains a slower, steady release rate thereafter. This parameter change enables a single dose to provide both rapid onset and prolonged therapeutic effect.
2Duration of action of moving object
If long-acting formulations with 8-14 hour duration are used, then therapeutic coverage is improved, but the drug release profile cannot provide adequate morning coverage when cognitive functions are needed
Solution Approach 1:
The patent divides the release profile into two temporal segments: an initial rapid release phase that ensures adequate morning coverage when cognitive functions are needed, and a subsequent sustained release phase that maintains therapeutic levels through the afternoon and evening. This temporal segmentation resolves the contradiction between duration and release profile control.
Solution Approach 2:
The patent implements a periodic release pattern where the drug is released in two distinct phases: an initial burst release followed by a sustained maintenance release. This periodic action ensures that therapeutic levels are achieved quickly in the morning and then maintained consistently throughout the day, addressing both duration and release profile control requirements.
3Ease of operation
If a single evening dose is administered, then compliance is improved and convenience is increased, but the drug must be delayed release for 4-12 hours before providing therapeutic effect
Solution Approach 1:
The patent segments the release timeline into an immediate release phase that occurs within hours of administration, providing rapid therapeutic onset, and a sustained release phase that maintains levels throughout the night and into the next day. This segmentation allows the single evening dose to provide both convenience and rapid therapeutic effect without excessive delay.
Solution Approach 2:
The patent implements preliminary action by designing the immediate release layer to deliver therapeutic levels of the drug quickly after evening administration, before the patient needs to wake up in the morning. This preliminary drug delivery ensures that when the patient wakes, therapeutic levels are already established, eliminating the perceived delay while maintaining administration convenience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions ensure a sustained therapeutic effect from waking through the active day, reducing side effects and improving cognitive function by maintaining consistent plasma concentrations, as measured by validated rating scales, with a single evening administration.
Implementation Method 1
coated with a sustained release layer and a delayed release layer, allowing for a single evening dose that provides a controlled release of the drug over 4 to 12 hours
Implementation Method 2
The delayed release allows the subject to sleep, and as the outer layer of the composition dissolves and the sustained release layer begins to lose some of its integrity, the drug starts to slowly release
Data Source
AI summary
Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.